Pyxis Oncology Files Q1 2025 10-Q
Ticker: PYXS · Form: 10-Q · Filed: 2025-05-15T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotech, financials, partnerships
TL;DR
Pyxis Oncology's Q1 2025 10-Q is in, check out their Pfizer and Mabwell deals.
AI Summary
Pyxis Oncology, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including details on its Pfizer License Agreement and Mabwell Agreement. Key financial data and operational segments were also disclosed.
Why It Matters
This filing provides investors with an update on Pyxis Oncology's financial health and strategic partnerships, crucial for understanding the company's progress in drug development.
Risk Assessment
Risk Level: medium — Biotech companies like Pyxis Oncology are inherently risky due to the long and uncertain drug development process and regulatory hurdles.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 2025-05-15 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Pyxis Oncology, Inc. (company) — Filer of the 10-Q
- Pfizer License Agreement (company) — Key agreement mentioned
- Mabwell Agreement (company) — Key agreement mentioned
- Boston, MA (location) — Company headquarters
FAQ
What is the current status of Pyxis Oncology's drug development pipeline as of March 31, 2025?
The filing does not provide specific details on the current status of the drug development pipeline beyond mentioning key agreements like the Pfizer License Agreement and Mabwell Agreement.
What were the significant financial results for Pyxis Oncology in the first quarter of 2025?
The provided text is an excerpt from the header of the 10-Q and does not contain specific financial results for the first quarter of 2025.
Are there any new material agreements or amendments to existing agreements mentioned in this filing?
The filing references the Pfizer License Agreement and Mabwell Agreement, but does not specify if there were new material agreements or amendments in this excerpt.
What is the company's primary business focus?
Pyxis Oncology, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is Pyxis Oncology, Inc. headquartered?
Pyxis Oncology, Inc. is headquartered at 321 Harrison Avenue, Boston, MA 02118.
From the Filing
0000950170-25-071996.txt : 20250515 0000950170-25-071996.hdr.sgml : 20250515 20250515074151 ACCESSION NUMBER: 0000950170-25-071996 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250515 DATE AS OF CHANGE: 20250515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 25948744 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 10-Q 1 pyxs-20250331.htm 10-Q 10-Q --12-31 Q1 false 0001782223 http://fasb.org/srt/2024#ChiefExecutiveOfficerMember http://fasb.org/us-gaap/2024#NetIncomeLoss 0001782223 us-gaap:RetainedEarningsMember 2024-12-31 0001782223 us-gaap:OperatingSegmentsMember pyxs:OtherMember 2025-01-01 2025-03-31 0001782223 pyxs:PfizerLicenseAgreementMember 2024-03-31 0001782223 pyxs:SharesReservedForFutureIssuanceMember 2025-03-31 0001782223 pyxs:PfizerLicenseAgreementMember 2025-03-31 0001782223 pyxs:PreFundedWarrantsMember srt:MaximumMember 2024-02-26 0001782223 pyxs:MabwellAgreementMember 2025-03-31 0001782223 us-gaap:EmployeeStockOptionMember 2024-12-31 0001782223 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001782223 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001782223 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001782223 pyxs:UniversityLicenseAgreementMember 2025-03-31 0001782223 pyxs:BiosionLicenseAgreementMember 2024-03-31 0001782223 pyxs:ApexigenReplacementWarrantsMember 2024-01-01 2024-03-31 0001782223 srt:MinimumMember 2025-01-01 2025-03-31 0001782223 pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2025-01-01 2025-03-31 0001782223 us-gaap:OperatingSegmentsMember pyxs:ProfessionalAndConsultantFeesMember 2025-01-01 2025-03-31 0001782223 us-gaap:OperatingSegmentsMember pyxs:PersonnelRelatedExpensesExcludingStockBasedCompensationMember 2024-01-01 2024-03-31 0001782223 pyxs:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2025-03-31 0001782223 2022-11-01 0001782223 pyxs:SimcereLicenseAgreementMember 2025-03-31 0001782223 us-gaap:USTreasurySecuritiesMember 2024-12-31 0001782223 pyxs:SaleOfRoyaltyRightsMember 2024-01-01 2024-03-31 0001782223 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001782223 pyxs:BiosionLicenseAgreementMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-03-28 2022-03-28 0001782223 2024-01-01 2024-03-31 0001782223 us-gaap:CommonStockMember 2023-12-31 0001782223 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001782223 pyxs:TwoThousandTwentyOneEquityIncentivePlanMember 2025-03-31 0001782223 us-gaap:OperatingSegmentsMember pyxs:PersonnelRelatedExpensesExcludingStockBasedCompensationMember 2025-01-01 2025-03-31 0001782223 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-03-31 0001782223 2025-05-14 0001782223 us-gaap:CommonStockMember pyxs:PreFundedWarrantsMember 2025-01-01 2025-01-31 0001782223 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001782223 srt:MaximumMember 2025-01-01 2025-03-31 0001782223 us-gaap:PrivatePlacementMember 2024-02-26 2024-02-26 0001782223 pyxs:DepreciationAndAmortizationMember 2025-01-01 2025-03-31 0001782223 pyxs:TwoThousandNineteenEquityIncentivePlanMember 2025-03-31 0001782223 us-gaap:RetainedEarningsMember 2024-03-31 0001782223 pyxs:WarrantOneMember 2025-03-31 0001782223 pyxs:ApexigenReplacementWarrantsMember 2025-01-01 2025-03-31 0001782223 us-gaap:RetainedEarningsMember 2023-12-31 0001782223 pyxs:ApexigenReplacementWa